-transparent.png){kind=logo}
1 The pharmacokinetics of subcutaneous cytosine arabinoside were compared with bolus intravenous injection and intravenous infusion in five patients with acute myelogenous leukaemia. 2 Subcutaneous cytosine arabinoside was rapidly absorbed and then declined biexponentially with initial and terminal half-lives similar to intravenous bolus injection. 3 Cytosine arabinoside levels declined rapidly after intravenous bolus and subcutaneous bolus injection, and fell below steady state infusion levels after a mean time of 40 min (intravenous bolus) and 100 min (subcutaneous injection).
Related Publications
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
September 1979,
British journal of clinical pharmacology,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
December 1989,
Bone marrow transplantation,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
November 1970,
British medical journal,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
June 1980,
British journal of cancer,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
February 1986,
Scandinavian journal of haematology,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
June 1971,
Lancet (London, England),
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
September 1995,
European journal of haematology,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
March 1970,
The Medical journal of Australia,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
June 1982,
Blood,
M L Slevin, and
E M Piall, and
G W Aherne, and
A Johnston, and
M C Sweatman, and
T A Lister
June 1977,
Clinical pharmacology and therapeutics,
